2023-06-06 14:00:00
Rare diseases: Ipsen joins forces with a start-up from the Imagine Institute
Ipsen will collaborate with Medicine, a start-up established within the Imagine Institute and supported by Inserm Transfert, as part of a research program called Hybridge. The objective is to discover new drug candidates, positioned in the treatment of rare diseases, one of the strategic therapeutic areas of the French laboratory. Eventually, the two entities hope to evaluate no less than fifty projects per year, with the aim of patenting one to three projects per year, all financed by Ipsen within the framework of this partnership. Each project will benefit from active support over a period of three years to see the emergence of a pharmacological molecular entity likely to enter the clinical development phase within eighteen months.
VOS INDICES
source
“By combining Ipsen’s strong capacity in R&D and Medetia’s solid experience in drug discovery and medicinal chemistry, we will be able to overcome our limits of clinical understanding and bring treatments to patients with rare diseases”underlined Christelle Huguet, Senior Vice-President, Director of Research, External Innovation and Early Development at Ipsen.
CDMO: Wuxi expands into Germany
Chinese CDMO continues to grow in Europe. While it has already invested heavily in Ireland, Wuxi has this time announced that it wants to continue to grow in Germany where the subcontractor has two production sites, in Leverkusen and Wuppertal. On this last site, dedicated to biological active substances, Wuxi plans to double the total capacities, bringing them from 12,000 to 24,000 liters, on a production area of 30,000 square meters. In Leverkusen, at its Chempark site specializing in aseptic filling, with a capacity of around ten million doses per year, Wuxi wants to add a second filling line. With these investments, the CDMO pursues its logic of diversification and dual sourcing for its production network.
“This investment in our facilities in Germany will add new capabilities and increase our production services, which will strengthen our ability to respond in time to our customers’ demands to bring their organic products to market”, said Chris Chen, CEO of Wuxi Biologics. The CDMO did not specify the amount of this investment or the schedule for future commissioning of the facilities.
Fibrosis: Boehringer Ingelheim signs a licensing agreement with SATT Nord
Boehringer Ingelheim entered into a license agreement with the SATT North for an innovative treatment of pulmonary fibrosis. Called K1K1, this protein is the result of an academic collaboration between the CNRS, the University of Lille, the Pasteur Institute of Lille, the University of Paris-Cité and the University of Pavia (Italy). The protein induces antifibrotic, regenerative and anti-inflammatory responses, it has shown therapeutic potential in vitro and in vivo. “Potentially being able to bring this new treatment to patients with the help of a strong partner is very gratifying for the research teams in Pavia, Lille and Paris, who have achieved this innovation within the framework of a long-term pan-European cooperation. term “, said Fabrice Lefebvre, Executive Chairman of SATT Nord. With this agreement, the financial details of which have not been specified, the German laboratory will be responsible for the research and development of K1K1 until its potential commercialization in pulmonary fibrosis.
The SATT Nord and the various academic partners will be able to continue to explore the potential of the protein on other chronic diseases. The treatment of pulmonary fibrosis is a strategic R&D target for Boehringer Ingelheim. The laboratory has a product currently in phase III, BI 1015550, against idiopathic pulmonary fibrosis.
Selected for you
1686073078
#letter #Ipsen #Wuxi #Boehringer #Ingelheim